Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 20 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 10 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 40 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 5 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 10 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 20 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 5 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 40 mg

Unione Europea - islandese - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - cannabidiol - lennox gastaut syndrome; epilepsies, myoclonic - antiepileptics, - epidyolex er ætlað til að nota eins og venjulega meðferð krampa í tengslum við lennox gastaut (lgs) eða dravet heilkenni (ds), með clobazami, fyrir sjúklinga 2 ára og eldri.

Unione Europea - islandese - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - liðagigt, liðagigt - Ónæmisbælandi lyf - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.